SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Go Long on Arena: obesity drug Belviq likely to be covered i
An SI Board Since November 2012
Posts SubjectMarks Bans Symbol
0 0 0 ARNA
Emcee:  SanDiegoBiotech Type:  Moderated
Aetna's recent decision to cover prescriptions for Arena's obesity drug Belviq is not an isolated event. Two important policy shifts at the federal level paved the way, and the policy shifts also bode well for more private insurance, Medicare and Medicaid coverage of prescription weight-loss drugs, including Belviq and Vivus, Inc.'s Qsymia. The shift in prescription coverage, a logical way to cut massive health costs caused by obesity-related disease and disability, is made possible by the FDA's approval of Belviq and Qsymia this summer.



The full story is at: sandiegobiotechnology.com
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):